Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Giant Biogene Holding Co's net current asset value per share for the quarter that ended in Dec. 2025 was HK$8.57.
The historical rank and industry rank for Giant Biogene Holding Co's Net Current Asset Value or its related term are showing as below:
HKSE:02367'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.98 Med: 8.9 Max: 13.39
Current: 3.02
During the past 7 years, the highest Price-to-Net-Current-Asset-Value Ratio of Giant Biogene Holding Co was 13.39. The lowest was 2.98. And the median was 8.90.
HKSE:02367's Price-to-Net-Current-Asset-Value is ranked better than 61% of 1059
companies
in the Consumer Packaged Goods industry
Industry Median: 4.1
vs HKSE:02367: 3.02
Giant Biogene Holding Co (HKSE:02367) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Giant Biogene Holding Co Net Current Asset Value Related Terms
Giant Biogene Holding Co Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Giant Biogene Holding Co's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Giant Biogene Holding Co Net Current Asset Value Chart
HKSE:02367 vs PG, CL, EL: Net Current Asset Value Comparison
For the Household & Personal Products subindustry, Giant Biogene Holding Co's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Giant Biogene Holding Co Price-to-Net-Current-Asset-Value vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Giant Biogene Holding Co's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Giant Biogene Holding Co's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of HK$8.57 mean?
Giant Biogene Holding Co (HKSE:02367) has a Net Current Asset Value of HK$8.57 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Giant Biogene Holding Co and its competitors. According to the industry distribution chart, Giant Biogene Holding Co ranks #413 out of 1059 companies in the Consumer Packaged Goods industry, placing it in the top 39%.
Is Giant Biogene Holding Co's Net Current Asset Value too high?
Giant Biogene Holding Co's current Net Current Asset Value is HK$8.57. Based on the distribution chart, Giant Biogene Holding Co ranks #413 out of 1059 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, Giant Biogene Holding Co has a GF Score™ of 85/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Giant Biogene Holding Co's Net Current Asset Value compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Giant Biogene Holding Co ranks #413 out of 1059 companies for Net Current Asset Value. This puts Giant Biogene Holding Co in the upper half of its industry. The industry median Net Current Asset Value is 4.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Consumer Packaged Goods company?
The median Net Current Asset Value among Consumer Packaged Goods companies is 4.10, based on 1,059 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Giant Biogene Holding Co and its competitors. For the Consumer Packaged Goods industry, the median Net Current Asset Value is 4.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Giant Biogene Holding Co's current Net Current Asset Value is HK$8.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Giant Biogene Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Giant Biogene Holding Co (HKSE:02367) is currently considered Possible Value Trap. The stock's GF Value™ is HK$68.03, compared to a current price of HK$24.46 — trading 64% below its estimated fair value. The current Net Current Asset Value is HK$8.57. Giant Biogene Holding Co's overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Giant Biogene Holding Co (HKSE:02367), the current Net Current Asset Value is HK$8.57 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Giant Biogene Holding Co (HKSE:02367) Overvalued in 2026?
Based on GuruFocus' analysis, Giant Biogene Holding Co stock appears to be undervalued.
The current stock price of HK$24.46 is trading 64% below its estimated GF Value™ of HK$68.03.
GuruFocus considers Giant Biogene Holding Co to be Possible Value Trap.
Key valuation signals for HKSE:02367:
Net Current Asset Value: HK$8.57
GF Value™: HK$68.03 vs. price of HK$24.46 (64% below fair value)
No single metric tells the full story. See the HKSE:02367 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Giant Biogene Holding Co Ltd designs, develops, and manufactures professional skin treatment products with recombinant collagen as the key bioactive ingredient. The company also develops and manufactures rare ginsenoside technology-based functional foods. The company utilizes proprietary synthetic biology technology to develop & manufacture multiple types of recombinant collagen & rare ginsenosides in-house. Bioactive ingredients offer a wealth of beauty & health properties such as skin repair, anti-aging, whitening, moisturizing, & immunity improvement, with a broad range of applications in the beauty & health sectors. The group is organised into a single business unit that mainly includes the research, development, manufacture, & sale of bioactive material-based beauty & health products.
85GF Score
Get the complete analysis for HKSE:02367
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02367 has been successfully added to your 
